Industry partnerships are crucial for more than just funding. Collaborating with pharmaceutical companies provides translation-focused questions that guide the design of advanced cell models, ensuring they are predictive, scalable, and compatible with real-world development workflows.

To demonstrate industrial-scale viability, Chai Discovery tested its antibody design model on 50 different targets. This focus on generalization, far beyond the typical 2-4 targets shown in academic research, is crucial for proving a model is not a statistical anomaly and is ready for real-world application.

AI startups may solve one piece of the 150-problem drug discovery puzzle exceptionally well. However, they lack the scale to run enough experiments to prove their specific edge provides overall value, making them likely acquisition targets for Big Pharma's toolkits.

Chai Discovery's partnership with Eli Lilly involves building a custom foundation model trained on Lilly's unique historical data. This signals a new collaboration model where AI firms act as specialized infrastructure builders, creating proprietary, data-moated AI for large pharmaceutical companies.

Chai Discovery's core philosophy is a direct application of "The Bitter Lesson" to biotech. They prioritize scaling compute, data, and simple models over creating complex, bespoke biological modules, betting that general-purpose learning methods will outperform human-engineered ones at scale.

To land large pharma partnerships, Turbine raised its first round to self-fund at-risk validation and early drug discovery. Proving their platform could generate novel, druggable IP was more persuasive than simply demonstrating predictive accuracy on existing experiments.

Despite claims of AI driving massive cost savings, industry experts like Eric Topol predict big pharma will not acquire major AI drug discovery companies in 2026. The dominant strategy is to build capabilities internally and form partnerships, signaling a cautious 'build and partner' approach over outright acquisition.

The relationship between AI startups and pharma is evolving rapidly. Previously, pharma engaged AI firms on a project-by-project, consulting-style basis. Now, as AI models for drug discovery become more robust, pharma giants are seeking to license them as enterprise-wide software suites for internal deployment, signaling a major inflection point in AI integration.

In the past, AI drug discovery startups often had to build their own drug pipeline to succeed. Now, a market shift is occurring where large pharmaceutical companies are actively acquiring or licensing specialized AI models and platforms, validating the business model of being a pure AI provider to the industry.